The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly O.
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
Martin J. Van Den Bent
Employment - AstraZeneca (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Boston Pharmaceuticals; carthera; chimerix; Genenta Science; Nerviano Medical Sciences
Research Funding - Abbvie (Inst)
 
Deborah T. Blumenthal
Travel, Accommodations, Expenses - Epitopoietic Research Corporation
Other Relationship - SERVIER
 
Mehdi Touat
Consulting or Advisory Role - Agios; Integragen; Novocure; SERVIER; Taiho Pharmaceutical
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; SERVIER
 
Katherine B. Peters
Consulting or Advisory Role - Blue Earth Diagnostics; NuvOx Pharma; Ono Pharmaceutical; Sapience Therapeutics; SERVIER
Research Funding - Abbvie; BioMimetix; Novocure; NuvOx Pharma; Sapience Therapeutics; SERVIER; Varian Medical Systems
Other Relationship - Eisai Europe
(OPTIONAL) Uncompensated Relationships - Vivacitas Oncology
 
Jennifer Leigh Clarke
Consulting or Advisory Role - Agios (Inst); SERVIER (Inst)
Research Funding - Agios (Inst); Merck (Inst); SERVIER (Inst)
 
Joe Sammy Mendez
No Relationships to Disclose
 
Liam Welsh
No Relationships to Disclose
 
Warren P. Mason
Honoraria - Apotex; Bayer; GlaxoSmithKline; Viatris
Consulting or Advisory Role - Novocure; Ono Pharmaceutical
Expert Testimony - Medcan
 
Andreas Felix Hottinger
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Novocure
Speakers' Bureau - Novocure
Research Funding - Novocure
 
Juan Manuel Sepulveda Sanchez
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - BMS; Cantex Pharmaceuticals
Research Funding - Cantex Pharmaceuticals (Inst); IDP Pharmaceuticals (Inst); Pfizer (Inst); Tilray (Inst); Varsity Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Wolfgang Wick
Consulting or Advisory Role - MSD Oncology (Inst); Roche/Genentech (Inst)
Research Funding - Apogenix (Inst); Pfizer (Inst); Roche (Inst)
 
Riccardo Soffietti
No Relationships to Disclose
 
Steven Schoenfeld
Employment - SERVIER
 
Dan Zhao
Employment - SERVIER
 
Shuchi Sumant Pandya
Employment - SERVIER
 
Lori Steelman
Employment - SERVIER
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Islam Hassan
Employment - SERVIER
 
Patrick Y. Wen
Consulting or Advisory Role - AstraZeneca; Bayer; Black Diamond Therapeutics; Boehringer Ingelheim; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Genenta Science; GlaxoSmithKline; Insightec; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Novocure; Nuvation Bio; Prelude Therapeutics; Prelude Therapeutics; Sagimet Biosciences; Sapience Therapeutics; Servier; Servier; Vascular Biogenics; VBI Vaccines
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; SERVIER; SonaCare Medical; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research